Business Description
Leap Therapeutics Inc
NAICS : 325414
SIC : 2836
ISIN : US52187K1016
Description
Leap Therapeutics Inc is in developing targeted antibody therapies for cancer treatment, focusing on inhibiting tumor-promoting pathways, targeting cancer-specific cell surface molecules, and activating the immune system against cancer cells. The company's lead program, DKN-01, targets Dickkopf-related protein 1 (DKK1) and is in clinical trials for esophagogastric, gynecologic, and colorectal cancers. Their second program, FL-301, targets Claudin18.2-expressing cells. Additionally, the company has two preclinical antibody programs, FL-302 and FL-501, aimed at developing transformative cancer treatments. Operating as a single segment, the company's sole focus is on developing innovative drugs to address unmet needs in cancer therapy. .
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 162.82 | |||||
| Equity-to-Asset | 0.81 | |||||
| Debt-to-Equity | 0.01 | |||||
| Debt-to-EBITDA | -0.01 | |||||
| Interest Coverage | N/A |
N/A
|
N/A
| |||
| Piotroski F-Score | 2/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | 4.9 | |||||
| 3-Year EPS without NRI Growth Rate | 14.8 | |||||
| 3-Year FCF Growth Rate | 21.2 | |||||
| 3-Year Book Growth Rate | -33 | |||||
| Future 3-5Y EPS without NRI Growth Rate Estimate | 32.37 |
Momentum Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 36.69 | |||||
| 9-Day RSI | 48.05 | |||||
| 14-Day RSI | 52.52 | |||||
| 6-1 Month Momentum % | -22.39 | |||||
| 12-1 Month Momentum % | 50.72 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 5.1 | |||||
| Quick Ratio | 5.1 | |||||
| Cash Ratio | 5.03 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -62.4 | |||||
| Shareholder Yield % | 0.16 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROE % | -91.25 | |||||
| ROA % | -76.84 | |||||
| ROIC % | -3219.87 | |||||
| 3-Year ROIIC % | 2291.64 | |||||
| ROC (Joel Greenblatt) % | -14251.85 | |||||
| ROCE % | -93.66 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PB Ratio | 1.89 | |||||
| Price-to-Tangible-Book | 1.89 | |||||
| EV-to-EBIT | -0.75 | |||||
| EV-to-EBITDA | -0.75 | |||||
| EV-to-FCF | -0.93 | |||||
| Price-to-Net-Current-Asset-Value | 1.95 | |||||
| Price-to-Net-Cash | 1.99 | |||||
| Earnings Yield (Greenblatt) % | -132.66 | |||||
| FCF Yield % | -40.05 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Leap Therapeutics Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | |||
| EPS (TTM) (€) | -1.613 | ||
| Beta | 0.82 | ||
| Volatility % | 142.99 | ||
| 14-Day RSI | 52.52 | ||
| 14-Day ATR (€) | 0.178767 | ||
| 20-Day SMA (€) | 2.996 | ||
| 12-1 Month Momentum % | 50.72 | ||
| 52-Week Range (€) | 1.32 - 4.26 | ||
| Shares Outstanding (Mil) | 38.26 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Leap Therapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Leap Therapeutics Inc Stock Events
| Event | Date | Price(€) | ||
|---|---|---|---|---|
| No Event Data | ||||
Leap Therapeutics Inc Frequently Asked Questions
What is Leap Therapeutics Inc(STU:5MC)'s stock price today?
The current price of STU:5MC is €3.02. The 52 week high of STU:5MC is €4.26 and 52 week low is €1.32.
When is next earnings date of Leap Therapeutics Inc(STU:5MC)?
The next earnings date of Leap Therapeutics Inc(STU:5MC) is 2024-11-13 Est..
Does Leap Therapeutics Inc(STU:5MC) pay dividends? If so, how much?
Leap Therapeutics Inc(STU:5MC) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers